Company
BARD1 Life Sciences Limited
Headquarters: South Perth, WA, Australia
Employees: 15
Market Cap
A$62.6 Million
AUD as of Jan. 1, 2024
US$42.6 Million
BARD1 Life Sciences Limited Categories
Australia Healthcare Diagnostics & ResearchAustralia Healthcare Australia Diagnostics & Research
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $207.62 B |
| Danaher | $171.89 B |
| Siemens Healthineers AG | $66.05 B |
| DexCom, Inc. | $46.50 B |
| IDEXX Laboratories, Inc. | $44.72 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
BARD1 Life Sciences Limited engages in the research, development, and commercialization of diagnostic products for the early detection of cancer to enhance patient outcomes in Australia. The company offers hTERT test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for ovarian and breast cancers, and research-stage projects for prostate and other cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in Notting Hill, Australia.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
BARD1 Life Sciences Limited has the following listings and related stock indices.
Stock: ASX: BD1 wb_incandescent